Skip to main content
. 2012 Jan;31(1):15–29. doi: 10.1089/dna.2011.1342

Table 1.

Synergism Analyses for Triple Combined Treatment with 17-AAG and Celecoxib with Radiation According to the Independent Action Model and Median-Drug Effect Method in Four Cancer Cell Lines and One Normal Cell Line

 
 Independent action model
 Median-drug effect method
Treatment group ESF OSF Ratio (ESF/OSF) p-Value Synergism CI Synergism
BEAS-2B cells
2.5 nM 17-AAG+20 μM Celx 0.809±0.037 0.769±0.083 1.05 0.426 No 0.57±0.108 Yes
2.5 nM 17-AAG+5 μM Celx+2 Gy IR 0.455±0.062 0.515±0.026 0.88 0.340 No 1.43±0.119 Antagonism
2.5 nM 17-AAG+20 μM Celx+2 Gy IR 0.276±0.016 0.266±0.012 1.04 0.240 No 1.00±0.011 Additive
A549 cells
2.5 nM 17-AAG+5 μM Celx 0.468±0.007 0.115±0.008 4.07 0.001 Yes 0.62±0.031 Yes
2.5 nM 17-AAG+1 μM Celx+2 Gy IR 0.250±0.015 0.095±0.010 2.62 0.100 Marginally yes 0.97±0.011 Yes
2.5 nM 17-AAG+2.5 μM Celx+2 Gy IR 0.245±0.004 0.048±0.007 5.12 0.010 Yes 0.91±0.009 Yes
2.5 nM 17-AAG+20 μM Celx+2 Gy IR 0.166±0.001 0.008±0.003 21.96 0.010 Yes 0.93±0.014 Yes
MOR-P cells
2.5 nM 17-AAG+7.5 μM Celx 0.419±0.025 0.242±0.021 1.73 0.050 Yes 0.64±0.005 Yes
2.5 nM 17-AAG+3.75 μM Celx+2 Gy IR 0.198±0.011 0.059±0.004 3.35 0.030 Yes 0.71±0.005 Yes
2.5 nM 17-AAG+7.5 μM Celx+2 Gy IR 0.160±0.003 0.025±0.0003 6.28 0.010 Yes 0.70±0.026 Yes
2.5 nM 17-AAG+20 μM Celx+2 Gy IR 0.073±0.001 0.007±0.003 10.33 0.010 Yes 0.78±0.009 Yes
NCI-H460 cells
2.0 nM 17-AAG+20 μM Celx 0.530±0.001 0.348±0.035 1.52 0.019 Yes 1.11±0.043 Antagonism
2.0 nM 17-AAG+5 μM Celx+2 Gy IR 0.241±0.002 0.056±0.006 4.31 0.010 Yes 0.85±0.001 Yes
2.0 nM 17-AAG+20 μM Celx+2 Gy IR 0.206±0.009 0.020±0.001 10.31 0.030 Yes 0.81±0.017 Yes
HCT-116 cells
20.0 nM 17-AAG+5 μM Celx 0.447±0.030 0.146±0.006 3.07 0.027 Yes 0.56±0.005 Yes
20.0 nM 17-AAG+5 μM Celx+2 Gy IR 0.205±0.002 0.020±0.001 10.48 0.003 Yes 0.81±0.003 Yes
20.0 nM 17-AAG+20 μM Celx+2 Gy IR 0.183±0.003 0.008±0.003 21.87 0.002 Yes 0.93±0.043 Yes

Mean±SE, 17-AAG; IC50, 10 μM≤celecoxib; within plasma concentration, 20 μM celecoxib; over plasma concentration. The p-value was statistically compared between ESF and OSF.

17-AAG, 17-(allylamino)-17-demethoxygeldanamycin; CI; combination index; IR, ionizing radiation; ESF, expected surviving fraction; OSF, observed surviving fraction.